Dosing of SLS-005 to Soon Begin in Phase 2b/3 HEALEY ALS Trial Arm

Dosing of SLS-005 to Soon Begin in Phase 2b/3 HEALEY ALS Trial Arm

302649

Dosing of SLS-005 to Soon Begin in Phase 2b/3 HEALEY ALS Trial Arm

Seelos Therapeutics has announced plans to start patient dosing in a pivotal Phase 2b/3 trial testing its experimental therapy SLS-005 (trehalose), designed to prevent protein clumping in cells, in adults with amyotrophic lateral sclerosis (ALS) by the close of September. The study is part of the HEALEY ALS Platform Trial (NCT04297683), the first multi-regimen trial in ALS, and will mark the fifth treatment to be simultaneously tested in the study. The simultaneous assessment of several potential therapies…

You must be logged in to read/download the full post.